Milvexian Fails to Reduce CV Events After ACS



Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.
Medscape Medical News



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *